TScan Therapeutics Management
Management criteria checks 0/4
TScan Therapeutics' CEO is Gavin MacBeath, appointed in Mar 2023, has a tenure of 1.67 years. total yearly compensation is $3.20M, comprised of 17.1% salary and 82.9% bonuses, including company stock and options. directly owns 0.093% of the company’s shares, worth $205.04K. The average tenure of the management team and the board of directors is 0.9 years and 1.6 years respectively.
Key information
Gavin MacBeath
Chief executive officer
US$3.2m
Total compensation
| CEO salary percentage | 17.1% |
| CEO tenure | 1.7yrs |
| CEO ownership | 0.09% |
| Management average tenure | less than a year |
| Board average tenure | 1.6yrs |
Recent management updates
Recent updates
Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet?
Nov 06
TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology
Aug 26Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price
Mar 23Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?
Feb 17TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target
Mar 11TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M
Aug 10TScan Therapeutics appoints Debora Barton as Chief Medical Officer
Jul 07Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation
May 22Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?
Jan 17We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate
Oct 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$111m |
| Jun 30 2024 | n/a | n/a | -US$104m |
| Mar 31 2024 | n/a | n/a | -US$97m |
| Dec 31 2023 | US$3m | US$545k | -US$89m |
| Sep 30 2023 | n/a | n/a | -US$88m |
| Jun 30 2023 | n/a | n/a | -US$82m |
| Mar 31 2023 | n/a | n/a | -US$73m |
| Dec 31 2022 | US$1m | US$450k | -US$66m |
| Sep 30 2022 | n/a | n/a | -US$62m |
| Jun 30 2022 | n/a | n/a | -US$61m |
| Mar 31 2022 | n/a | n/a | -US$57m |
| Dec 31 2021 | US$1m | US$400k | -US$49m |
| Sep 30 2021 | n/a | n/a | -US$42m |
| Jun 30 2021 | n/a | n/a | -US$34m |
| Mar 31 2021 | n/a | n/a | -US$29m |
| Dec 31 2020 | US$533k | US$350k | -US$26m |
Compensation vs Market: Gavin's total compensation ($USD3.20M) is above average for companies of similar size in the US market ($USD1.46M).
Compensation vs Earnings: Gavin's compensation has increased whilst the company is unprofitable.
CEO
Gavin MacBeath (54 yo)
1.7yrs
Tenure
US$3,196,054
Compensation
Dr. Gavin MacBeath, Ph D., serves as CEO & Director of TScan Therapeutics, Inc. from May 24, 2023 and served as its Interim Principal Financial Officer since July 21, 2023 until 2023. Dr. MacBeath was Acti...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.7yrs | US$3.20m | 0.093% $ 205.0k | |
| Chief Legal & Strategy Officer and Company Secretary | 3.2yrs | US$1.58m | 0.0088% $ 19.4k | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Advisory Board | no data | no data | no data | |
| CFO & Treasurer | less than a year | no data | no data | |
| Chief Technology Officer | less than a year | no data | no data | |
| Senior Vice President of Human Resources | 4.8yrs | no data | no data | |
| Senior VP & Head of Translational Medicine | 1.8yrs | no data | no data | |
| Senior Vice President & Head of Quality | less than a year | no data | no data | |
| Senior VP & Head of Development Operations | less than a year | no data | no data | |
| Senior Vice President of Discovery | less than a year | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
0.9yrs
Average Tenure
54yo
Average Age
Experienced Management: TCRX's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.5yrs | US$3.20m | 0.093% $ 205.0k | |
| Co-Founder & Chairman of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Chair of the Board | 3.7yrs | US$123.17k | 0% $ 0 | |
| Independent Director | 3.7yrs | US$132.59k | 0% $ 0 | |
| Director | less than a year | no data | no data | |
| Director | 1.6yrs | US$121.74k | 0.13% $ 288.4k | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | US$90.90k | no data | |
| Independent Director | 3.5yrs | US$113.53k | 0% $ 0 |
1.6yrs
Average Tenure
66.5yo
Average Age
Experienced Board: TCRX's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.